Research and Markets: Stakeholder Opinions: Skin Infections - Where In The Antibacterial Lifecycle?DUBLIN, Ireland -- Prescriptions Associated with Skin Infections Account for Only a Small Percentage of Total Community Antibacterial antibacterial /an·ti·bac·te·ri·al/ (-bak-ter´e-al) destroying or suppressing growth or reproduction of bacteria; also, an agent that does this. an·ti·bac·te·ri·al adj. Sales (e.g. 3% of US Drugstore Sales) Research and Markets (http://www.researchandmarkets.com) has announced the addition of Stakeholder stakeholder n. a person having in his/her possession (holding) money or property in which he/she has no interest, right or title, awaiting the outcome of a dispute between two or more claimants to the money or property. Opinions: Skin Infections - Where In The Antibacterial Lifecycle? to their offering. Introduction Bacterial skin and skin structure infections are among the most common infections treated within the community setting. There are a wide range of different types of infection, each with individual symptoms, epidemiology epidemiology, field of medicine concerned with the study of epidemics, outbreaks of disease that affect large numbers of people. Epidemiologists, using sophisticated statistical analyses, field investigations, and complex laboratory techniques, investigate the cause and etiology etiology /eti·ol·o·gy/ (e?te-ol´ah-je) 1. the science dealing with causes of disease. 2. the cause of a disease. . However, the majority require antibacterial treatment and, as a result, represent potential lucrative targets for novel product development and indication expansion. Scope - Disease definitions, symptoms, epidemiology and risk factors for key skin and skin structure infections - Detailed seven country market analysis by class and indication, including volume and value assessments - Breakdown of prescriptions for key skin infections by physician type, across the seven major markets - Strategic analysis and recommendations for maximizing the potential of the skin infections sector Highlights Prescriptions associated with skin infections account for only a small percentage of total community antibacterial sales (e.g. 3% of US drugstore sales). Companies developing and marketing broad-spectrum antibacterials should consider skin infections as a secondary target, focusing primary resources on higher value indications. High unmet un·met adj. Not satisfied or fulfilled: unmet demands. need in the management of skin infections involving resistant pathogens increases the likelihood of gaining fast-track designation in the US. The potential for rapid market entry, reduced development costs and focused physician targets presents an attractive proposition for smaller players with limited resources. There is a clear lack of synergy The enhanced result of two or more people, groups or organizations working together. In other words, one and one equals three! It comes from the Greek "synergia," which means joint work and cooperative action. between acne acne, common inflammatory disease of the hair follicles and sebaceous glands characterized by blackheads, whiteheads, pustules, nodules and, in the more severe forms, by cysts and scarring. The lesions appear on the face, neck, back, chest, and arms. and other bacterial infections, in terms of prescribing physicians and focus classes. Companies involved in antibacterial product development or life cycle management should bear this in mind when considering indication expansions. Reasons to Purchase - Effectively prioritize pri·or·i·tize v. pri·or·i·tized, pri·or·i·tiz·ing, pri·or·i·tiz·es Usage Problem v.tr. To arrange or deal with in order of importance. v.intr. skin infections within your antibacterial portfolio with detailed prescription and sales data - Target detailing campaigns more effectively with in-depth understanding of physicians involved in the management of skin infections - Identify key strategies to maximize the potential of bacterial skin infections bacterial skin infection Cellulitis, see there for both key players and new market entrants Report Contents: Chapter 1 Executive Summary Chapter 2 Disease Definition and Epidemiology Chapter 3 Presentation, Diagnosis and Treatment Chapter 4 Market Analysis by Drug Class Chapter 5 Market Analysis by Indication Chapter 6 Strategic Analysis For more information visit http://www.researchandmarkets.com/reports/c4926 |
|
||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion